|  |  |
| --- | --- |
| Clone | 121SLE |
| Source | Mouse Monoclonal |
| Cat #  | PM206-6ml RTUPM206-3ml RTUCM206-0.1ml ConcCM206-0.5ml Conc HAM206-3ml RTUHAM206-6ml RTU |
| Regulatory Status | IVD |

CA19.9 (121SLE)

**Intended Use:**

This antibody is intended for use to qualitatively identify CA19.9 antigen by light microscopy in formalin fixed, paraffin embedded tissue sections using immunohistochemical detection methodology. Interpretation of any positive or negative staining must be complemented with the evaluation of proper controls and must be made within the context of the patient’s clinical history and other diagnostic tests. A qualified pathologist must perform evaluation of the test.

**Summary and Explanation:**

CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewis a and/or Lewis b blood group antigens. In normal tissues, sialyl Lewis a antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings.

**Immunogen:** Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated
 from an ovarian cyst of a Lewis A+B- patient (0Le).

**Isotype:** Mouse IgM,kappa

**Reagent Provided:
 Concentrated format:** Antibody to CA19.9 is diluted in antibody diluent, with 1% bovine serum
 albumin (BSA) and 0.05% sodium azide (NaN3). Recommended dilutions:
 1:100.The antibody dilution and protocol may vary depending on the specimen
 preparation and specific application. Optimal conditions should be
 determined by individual laboratory.

 **Pre-diluted format:** PathnSitu ready to use antibodies are pre tittered to optimal staining
 conditions. Further dilution may loose the activity and may yield to sub
 optimal staining.

**Storage Recommendations:** Store at 2°-8°C. Do not use after expiration date provided on the vial.

**Staining Recommendations:
 Antigen Retrieval Solution:** Use **Tris-EDTA Buffer** **(PathnSitu Cat # PS009)** as antigen retrieval
 solution Heat Retrieval Method: Retrieve sections under steam pressure
 for 15 min using PathnSitu’s MERS (Multi Epitope Retrieval System) then
 allow solution to cool for 10 minutes then transfer tissue sections/slides to
 distilled water.

**Primary Antibody:**  Cover the tissue sections with primary antibody and incubate for 30
 min at room temperature when used PathnSitu PolyExcel Detection
 System.

**Detection System:** Refer to PathnSitu PolyExcel detection system protocol or manufacturer’s detection kit staining protocol when used other vendor detection system.

**Cellular Localization:** Cytoplasm

**Positive Control:** Stomach, Colon Ca

**Troubleshooting:** Follow the antibody specific protocol recommendations according to data sheet provided. If unusual results occur, contact PathnSitu Technical Support at 040-2701 5544 or techsupport@pathnsitu.com.

**Limitations and Warranty:** There are no warranties, expressed or implied, which extend beyond this
 description. PathnSitu is not liable for property damage, personal injury, or
 economic loss caused by this product.

**Bibliography:**  1. Blood transfusion and Immunohaematology, Ph. Rouger, D Anstee and Ch. Salmon (Eds).
 Arnette, France 30 (5): 353-720 (1987).
2. Tumor Biol 19(5): 390420, (1998; TD-6 Workshop Report).